Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilorasertib + carboplatin
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ilorasertib (ABT-348) is an orally active, ATP-competitive small molecule multikinase inhibitor that primarily targets Aurora kinases (A, B, and C), as well as members of the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) families. Carboplatin is a platinum-based chemotherapeutic agent that functions by interfering with DNA replication through the formation of DNA cross-links. This combination therapy was developed by AbbVie (formerly Abbott) and evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors. The study aimed to determine the safety, pharmacokinetics, and maximum tolerated dose of the combination. However, the development program for ilorasertib, including its use in combination with carboplatin, was ultimately discontinued.
- Other names
- ilorasertib + carboplatin
02
Targets
AURKA (Aurora kinase A)AURKB (Aurora kinase B)AURKC (Aurora kinase C)CSF1R (Macrophage colony-stimulating factor receptor)DNAFLT3 (Fms related receptor tyrosine kinase 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)SFK (SRC family kinases)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on ilorasertib + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilorasertib + carboplatin.